Transgene

Transgene EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Transgene (TNG.PA) as of Nov 19, 2026 is -6.60. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -8.24 — a change of -19.95% (higher).

EV/EBITDA

-6.60

YoY

-19.95%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Transgene is 2024 -6.60 . EV/EBITDA (Enterprise Value to EBITDA) of Transgene was 2023 -8.24 . It decreases by -19.95% higher compared to the previous year.

The Transgene EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2017
-8.96 EUR
Jan 1, 2018
25.95 EUR
Jan 1, 2019
-8.71 EUR
Jan 1, 2020
-9.52 EUR
Jan 1, 2021
-8.62 EUR
Jan 1, 2022
-7.78 EUR
Jan 1, 2023
-8.24 EUR
Jan 1, 2024
-6.60 EUR
The Transgene EV/EBITDA history
YEAREV/EBITDAYoY
-6.60-19.95%
-8.24+6.01%
-7.78-9.82%
-8.62-9.40%
-9.52+9.25%
-8.71-133.57%
25.95-389.73%
-8.96-17.70%
-10.88+17.39%
-9.27+43.29%
-6.47—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

EV/EBITDA (Enterprise Value to EBITDA) of Transgene is -6.60 in 2024.

EV/EBITDA (Enterprise Value to EBITDA) of Transgene changed from -8.24 to -6.60, representing a -19.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Transgene since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Transgene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Transgene

All Key Metrics — Transgene